{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+HR%2B%2FHER2-+Breast+Cancer&page=5", "query": { "condition": "Advanced HR+/HER2- Breast Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 100, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+HR%2B%2FHER2-+Breast+Cancer&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+HR%2B%2FHER2-+Breast+Cancer&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T18:54:43.453Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07029399", "title": "A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HR+ Breast Cancer", "Triple Negative Breast Cancer (TNBC)", "CCNE1 Amplified Advanced Solid Tumors", "HR+ HER2- Breast Cancer" ], "interventions": [ { "name": "NKT5097 CDK2/CDK4 dual degrader", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NiKang Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 361, "start_date": "2025-03-25", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-11T18:54:43.453Z", "location_count": 18, "location_summary": "Duarte, California • La Jolla, California • Denver, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07029399" }, { "nct_id": "NCT06974604", "title": "Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Lung Neoplasms" ], "interventions": [ { "name": "Dexamethasone oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-10-22", "completion_date": "2029-05-31", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-10-11T18:54:43.453Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974604" }, { "nct_id": "NCT06975371", "title": "Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced/Metastatic HER2-negative Breast Cancer" ], "interventions": [ { "name": "No drug", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1415, "start_date": "2025-04-14", "completion_date": "2025-08-05", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-10-11T18:54:43.453Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06975371" }, { "nct_id": "NCT07368998", "title": "To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-02-18", "completion_date": "2031-10-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-11T18:54:43.453Z", "location_count": 4, "location_summary": "Los Angeles, California • Jacksonville, Florida • Kansas City, Missouri + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07368998" }, { "nct_id": "NCT05262400", "title": "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors" ], "interventions": [ { "name": "PF-07220060 + PF-07104091 combination dose escalation", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + fulvestrant dose expansion", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + letrozole dose expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2022-03-14", "completion_date": "2027-02-26", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-11T18:54:43.453Z", "location_count": 12, "location_summary": "Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05262400" }, { "nct_id": "NCT07174336", "title": "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "LY4064809", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2025-12-22", "completion_date": "2033-05", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-11T18:54:43.453Z", "location_count": 129, "location_summary": "Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 110 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07174336" }, { "nct_id": "NCT02692755", "title": "Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hormone Receptor Positive HER-2 Negative Breast Cancer" ], "interventions": [ { "name": "Palbociclib + Letrozole or Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 35, "start_date": "2016-09", "completion_date": "2021-03-23", "has_results": true, "last_update_posted_date": "2021-09-28", "last_synced_at": "2026-10-11T18:54:43.453Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02692755" }, { "nct_id": "NCT04505826", "title": "A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hormone Receptor Positive Breast Carcinoma", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "OP-1250", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Olema Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2020-08-13", "completion_date": "2024-07-30", "has_results": true, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-11T18:54:43.453Z", "location_count": 15, "location_summary": "Los Angeles, California • Aurora, Colorado • Deerfield Beach, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04505826" }, { "nct_id": "NCT07223476", "title": "Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1926, "start_date": "2024-03-29", "completion_date": "2024-07-01", "has_results": false, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-10-11T18:54:43.453Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223476" }, { "nct_id": "NCT03854903", "title": "WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Hormone Receptor Positive Breast Cancer" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 19, "start_date": "2019-04-01", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-10-11T18:54:43.453Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03854903" } ] }